Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICAÂ®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients